Treatment of Neonatal Abstinence Syndrome With Clonidine Versus Morphine as Primary Therapy

Running, not enrolling · Phase 4

Conditions studied: Neonatal Abstinence Syndrome

In brief

The purpose of this study is to show non-inferiority between two medications used for medical treatment of withdrawal seen in Neonatal Abstinence Syndrome (NAS), Clonidine and Morphine Sulfate (used in routine care) on length of treatment for NAS .

Key facts

Study ID

NCT03092011

Run by

The Cooper Health System

People needed

69

Starts

2018-02-21

Expected to finish

2026-12-01

Last updated by the study team

2024-10-15

Who can join

Age: any, up to 0. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Born at Cooper University Hospital
• Greater than or equal to 35 weeks gestation age
• Admitted to the NICU or Transitional nursery
• Mothers admitted to using illicit substances or prescription medications (which can result in withdrawal symptoms) while pregnant and/or had a positive urine drug screen during pregnancy.
• Babies being started on medication to control withdrawal symptoms of NAS.
• No congenital anomalies or neurologic condition (i.e. hypoxic-ischemic encephalopathy, seizures, meningitis etc.)

You may not qualify if…

• Premature infants <35 week gestational age
• Infants with major congenital abnormalities
• Blood pressure instability
• Major medical conditions

Where it is running

• Cooper University Hospital — Camden, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.